AAAAAA
Results:
1-22
|
Results: 22
Authors:
Chassevent, A
Jourdan, ML
Romain, S
Descotes, F
Colonna, M
Martin, PM
Bolla, M
Spyratos, F
Citation: A. Chassevent et al., S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: A standardizedflow cytometric study, CLIN CANC R, 7(4), 2001, pp. 909-917
Authors:
Ferrero-Pous, M
Trassard, M
Le Doussal, V
Hacene, K
Tubiana-Hulin, M
Spyratos, F
Citation: M. Ferrero-pous et al., Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients, APPL IMMUNO, 9(3), 2001, pp. 267-275
Authors:
Bieche, I
Parfait, B
Nogues, C
Andrieu, C
Vidaud, D
Spyratos, F
Lidereau, R
Vidaud, M
Citation: I. Bieche et al., The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients, ONCOGENE, 20(47), 2001, pp. 6955-6959
Authors:
Broet, P
Romain, S
Daver, A
Ricolleau, G
Quillien, V
Rallet, A
Asselain, B
Martin, PM
Spyratos, F
Citation: P. Broet et al., Thymidine kinase as a proliferative marker: Clinical relevance in 1,692 primary breast cancer patients, J CL ONCOL, 19(11), 2001, pp. 2778-2787
Authors:
Bieche, I
Onody, P
Lerebours, F
Tozlu, S
Hacene, K
Andrieu, C
Vidaud, M
Tubiana-Hulin, M
Spyratos, F
Lidereau, R
Citation: I. Bieche et al., ERBB2 status and benefit from adjuvant tamoxifen in ER alpha-positive postmenopausal breast carcinoma, CANCER LETT, 174(2), 2001, pp. 173-178
Authors:
Bagwell, CB
Clark, GM
Spyratos, F
Chassevent, A
Bendahl, PO
Stal, O
Killander, D
Jourdan, ML
Romain, S
Hunsberger, B
Baldetorp, B
Citation: Cb. Bagwell et al., Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens, CYTOMETRY, 46(3), 2001, pp. 121-135
Authors:
Briffod, M
Le Doussal, V
Spyratos, F
Citation: M. Briffod et al., Immunohistochemical determination of hormonal receptors on cell-blocks from fine-needle cytopunctures of breast carcinoma, B CANCER, 88(10), 2001, pp. 1028-1035
Authors:
Fina, F
Romain, S
Ouafik, LH
Palmari, J
Ben Ayed, F
Benharkat, S
Bonnier, P
Spyratos, F
Foekens, JA
Rose, C
Citation: F. Fina et al., Frequency and genome load of Epstein-Barr virus in 509 breast cancers fromdifferent geographical areas, BR J CANC, 84(6), 2001, pp. 783-790
Authors:
Spyratos, F
Ferrero-Pous, M
Tubiana-Hulin, M
Hacene, K
Citation: F. Spyratos et al., More about: Prognostic importance of low c-erbB2 expression in breast tumors - Response, J NAT CANC, 92(17), 2000, pp. 1443-1444
Authors:
Ferrero-Pous, M
Hacene, K
Bouchet, C
Le Doussal, V
Tubiana-Hulin, M
Spyratos, F
Citation: M. Ferrero-pous et al., Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis, CLIN CANC R, 6(12), 2000, pp. 4745-4754
Authors:
Spyratos, F
Andrieu, C
Vidaud, D
Briffod, M
Vidaud, M
Lidereau, R
Bieche, I
Citation: F. Spyratos et al., CCND1 mRNA overexpression is highly related to estrogen receptor positivity but not to proliferative markers in primary breast cancer, INT J B MAR, 15(3), 2000, pp. 210-214
Authors:
Floiras, JL
Hacene, K
Turpin, F
Spyratos, F
Citation: Jl. Floiras et al., Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?, INT J B MAR, 15(2), 2000, pp. 135-138
Authors:
Bouchet, C
Hacene, K
Martin, PM
Becette, V
Tubiana-Hulin, M
Lasry, S
Oglobine, J
Spyratos, F
Citation: C. Bouchet et al., Plasminogen activator system type-urokinase and its prognostic impact of adissemination risk index in breast cancer., PATH BIOL, 48(9), 2000, pp. 825-831
Authors:
Le Goff, JM
Lavayssiere, L
Rouesse, J
Spyratos, F
Citation: Jm. Le Goff et al., Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks, ANTICANC R, 20(3B), 2000, pp. 2213-2218
Authors:
Romain, S
Spyratos, F
Descotes, F
Daver, A
Rostaing-Puissant, B
Bougnoux, P
Colonna, M
Bolla, M
Martin, PM
Citation: S. Romain et al., Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: A retrospective multicenter study, INT J CANC, 87(6), 2000, pp. 860-868
Authors:
Mauriac, L
Blanc-Vincent, MP
Luporsi, E
Cutuli, B
Fourquet, A
Garbay, JR
Giard, S
Spyratos, F
Zafrani, B
Dilhuydy, JM
Citation: L. Mauriac et al., Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer, B CANCER, 87(6), 2000, pp. 469-490
Authors:
Ferrero-Pous, M
Hacene, K
Tubiana-Hulin, M
Spyratos, F
Citation: M. Ferrero-pous et al., Prognostic importance of low c-erbB2 expression in breast tumors, J NAT CANC, 91(18), 1999, pp. 1584-1585
Authors:
Bouizar, Z
Spyratos, F
De Vernejoul, MC
Citation: Z. Bouizar et al., The parathyroid hormone-related protein (PTHrP) gene: Use of downstream TATA promotor and PTHrP 1-139 coding pathways in primary breast cancers vary with the occurrence of bone metastasis, J BONE MIN, 14(3), 1999, pp. 406-414
Authors:
Bouchet, C
Hacene, K
Martin, PM
Becette, V
Tubiana-Hulin, M
Lasry, S
Oglobine, J
Spyratos, F
Citation: C. Bouchet et al., Dissemination risk index based on plasminogen activator system components in primary breast cancer, J CL ONCOL, 17(10), 1999, pp. 3048-3057
Authors:
Spyratos, F
Romain, S
Rostaing-Puissant, B
Daver, A
Colonna, M
Descotes, F
Martin, PM
Bougnoux, P
Roth, H
Bolla, M
Citation: F. Spyratos et al., Standardization and quality control in the evaluation of proliferation parameters in T1T2, N0N1, M0 breast cancer: multicentric retrospective study 1. DNA synthesis enzyme activities, B CANCER, 86(7-8), 1999, pp. 678-684
Authors:
Chassevent, A
Jourdan, ML
Ferrero-Pous, M
Colonna, M
Romain, S
Spyratos, F
Roth, H
Bolla, M
Citation: A. Chassevent et al., Standardization and quality control in the evaluation of proliferation parameters in T1T2, N0N1, M0 breast cancer: multicentric retrospective study II. DNA-ploidy and S-phase fraction, B CANCER, 86(7-8), 1999, pp. 685-691
Authors:
Broet, P
Spyratos, F
Romain, S
Quillien, V
Daver, A
Ricolleau, G
Rallet, A
Toulas, C
Asselain, B
Citation: P. Broet et al., Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study, BR J CANC, 80(3-4), 1999, pp. 536-545
Risultati:
1-22
|